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The Editorial on the Research Topic
Unraveling Neuroprotective and Neurodegenerative Signals in Neurodegeneration
Our understanding of the etiology of human neurodegenerative disorders is limited by the necessity
to infer an active sequence of events, often expressed over protracted periods of time, from a
collection of still-life images that often represent the end of the sequence with no clear view of
how we got there. Adding to the collective confusion, it often is not clear whether our measures
of nervous system structure and function at a given point in time represent active contributors to
degeneration, the tombstones reflecting consequences of degeneration, active attempts to protect
the nervous system, products of failed protection, or unrelated events. As a result, we rely on
observations and manipulations of fragments of the process in experimental models and human
samples, pieced together to create versions of what is possible. In this collection of articles, the
iterative process is on full display, with a focus on Alzheimer’s disease, Parkinson’s disease, and
related disorders, and reports ranging from tools to mechanisms to treatment.
ALZHEIMER’S DISEASE AND RELATED DISORDERS
For decades, the relative contributions and timing of accumulation of β-amyloid peptides (senile
plaques) and oligomerization of the microtubule associated protein tau (neurofibrillary tangles)
has been an open question in the etiology of Alzheimer’s disease (AD). In this collection, Khan
and Bloom review evidence suggesting that tau plays a central pathological role in AD as the
mediator of β-amyloid neuronal toxicity. The authors discuss reports indicating that accumulation
of β-amyloid oligomers affects tau’s biological function, promoting microtubule instability, axonal
transport defects, aberrant activation of kinases and synaptotoxicity. The authors argue that tau
plays a central role in a “pathogenic signaling nexus that underlies AD.”
Sabbagh and Dickey discuss the known structural features and posttranslational modifications
that contribute to tau function and toxicity in AD and other tauopathies. The authors review
evidence indicating that posttranslational modifications and the function of chaperones influence
tau structural dynamics, transitioning from its physiological conformation to pathological
structures that lead to neurodegeneration.
The structural dynamics of tau is of great interest as a means to differentiate between normal
and pathological tau. The contribution of Brelstaff et al. describes the use of pentameric formyl
thiophene acetic acid (pFTAA), an amyloid specific fluorescent dye, to detect fibrillary tau
in living neurons. The authors demonstrate that pFTAA can be used as a tool to assess the
efficacy of compounds that block the accumulation of pathological tau and/or tau-mediated
neurodegeneration in cultured neurons.
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While, pFTAA specificity for amyloid proteins is of significant
value in cell models, it will not distinguish between pathological
β-amyloid and tau proteins in AD brain, limiting applications
to in vivo imaging. Shimojo et al. review the advances in PET
and fluorescence imaging as tools for the diagnosis of AD.
The authors discuss the advantages of these techniques for
detecting and dissecting disease progression in living organisms.
The authors also discuss the limitations and pitfalls of PET
and fluorescence imaging, providing a technical framework to
improve the available technology.
Despite progress in the understanding of structural dynamics
and detection of β-amyloid and tau in the context of the disease
state, it remains unclear if the observed pathological structures
are toxic or neuroprotective. Both pathological hallmarks also
have been detected in cognitively normal individuals, suggesting
that compensatory plasticity could mask the undergoing
pathological process and, avert clinical presentation. Here, Avila
et al. propose an alternate neuronal axis to explain how cognitive
capacity is maintained in asymptomatic individuals with plaques
and tangles. The authors argue that activation of the “default
mode network (DMN)” bypasses the role of the AD-damaged
entorhinal cortex, preserving function.
However, the progression of pathological processes could
lead to synaptotoxicity, affecting the compensatory role of the
DMN and contributing to clinical presentation. In this context,
the role of hyperactivation of NMDA receptors and increased
glutamate in AD is reviewed by Lewerenz and Maher. The
authors extensively discuss evidence supporting the role of
glutamate toxicity in neurodegeneration.
Study of other pathophysiologies associated with AD,
in addition to β-amyloid and tau, hold potential to lead to
development of tools that contribute to the understanding,
diagnosis and treatment of the disease. For example, the
contribution by Vega reviews published work that links the novel
amyloid EFhd2 protein to AD and other neurodegenerative
diseases. EFhd2 is a calcium binding protein which exhibits
altered expression in AD and is found to co-aggregate with
tau. Weinberg et al. present evidence that specific microRNAs
may provide neuroprotection from β-amyloid toxicity through
regulation of translation of specific RNA transcripts. In this
study, they focus on sirtuin 1 and its neuroprotective role
in β-amyloid toxicity. Thus, the understanding of alternate
molecular mechanisms could contribute to unravel the
pathophysiology of AD and related disorders.
PARKINSON’S DISEASE AND RELATED
DISORDERS
Like AD, Parkinson’s disease (PD) is a multi-factorial syndrome
that likely arrives at its clinical phenotype via a variety of
combinations of risk factors and molecular pathways. One
consistent feature of post-mortem PD brain is evidence of
inflammation. Whether neuroinflammation contributes to PD
neurodegeneration as cause, effect, or both, remains a topic of
debate. Here, Walker et al. present findings from a quantitative
multiplex protein analysis of 160 molecules, including those
associated with inflammation, in substantia nigra (SN) and
striatum of neuropathological confirmed cases of PD, incidental
Lewy body disease (ILBD) and controls. The patterns of
bidirectional changes in inflammation and growth factor proteins
differ in SN and striatum, including novel changes in markers
suggestive of reduced vascular integrity.
The accumulation of cytoplasmic protein aggregates
containing alpha-synuclein (α-syn) in affected neurons is a
neuropathological hallmark of PD. Delenclos et al. used a
protein fragment complementation assay to monitor α-syn
aggregates in vivo, providing a suitable model for therapeutic
testing. However, whether α-syn aggregation elicits a toxic
effect, neuroprotective mechanism, or both is debatable. While
the association of α-syn with genetic forms of PD has been
interpreted as disease-related toxic-gain-of-function, it is
conceivable that sequestering the protein in aggregates results in
toxic-loss-of-function. The contribution by Collier et al. presents
new evidence from nonhuman primates consistent with the view
that knock-down of endogenous α-syn in the nigrostriatal system
faithfully reproduces the pattern of degeneration observed in
PD.
Finally, the contribution of Lazzara and Kim reviews evidence
addressing the neuroprotective potential of lithium for PD, AD
and other neurodegenerative disorders. With the advent of drug
repurposing as a strategy for a quicker path to clinical translation,
many considered “dirty drugs,” due to side-effect profile and non-
specificity for a single target, as the compounds best suited to
treatment of complex, multi-factorial diseases. For the example
of lithium, effects favoring reduced oxidative stress, reduced
inflammation, inhibition of apoptosis, increased authophagy
and stimulation of neurotrophic factors all address interacting
systems implicated in neurodegenerative disease. Perhaps, for
complex syndromes, drugs with highly focused targets may
not be the best approach to treatment. The alternate approach
of “dirty drugs” for complex diseases may hold significant
value.
To make progress in our understanding of the complex
etiology of AD, PD, and related disorders, it is clear that an
appreciation of the web of interactions amongmultiplemolecular
pathways including neuroinflammation, energy metabolism,
proteostasis and others will be critical to unraveling the mixed
contributions of neuroprotective and neurodegenerative signals,
supporting therapeutic efforts to harness one and limit the other.
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